Abigail Sloan Devlin

Title: Abigail Sloan Devlin: Innovator in Batrachotoxin Analogues

Introduction

Abigail Sloan Devlin is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of pharmacology through her innovative work on batrachotoxin analogues. Her research focuses on compounds that modulate the activity of sodium channels, which are crucial for various physiological processes.

Latest Patents

Abigail holds a patent for "Batrachotoxin analogues, compositions, uses, and preparation thereof." This patent includes compounds related to batrachotoxin, particularly analogs that can modulate sodium channel activity. The pharmaceutical compositions she developed include vehicles that enhance transdermal permeation of the compounds. These compounds are particularly useful in treating conditions that require reduced neuronal activity or muscular relaxation. They also have applications in treating ailments associated with voltage-gated sodium channel enhancement and pain management.

Career Highlights

Abigail is affiliated with Leland Stanford Junior University, where she continues her research and development in pharmacological innovations. Her work has garnered attention for its potential therapeutic applications and contributions to medical science.

Collaborations

Abigail has collaborated with notable colleagues, including Justin Du Bois and Matthew M Logan. These partnerships have further enriched her research and expanded the impact of her innovations.

Conclusion

Abigail Sloan Devlin is a trailblazer in the field of pharmacology, with her work on batrachotoxin analogues paving the way for new treatments in medicine. Her contributions highlight the importance of innovation in addressing complex health challenges.